Source-grounded facts extracted from Janux Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Janux Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $24.4 million for the quarter ended March 31, 2026.
“Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.”
Janux Therapeutics, Inc. entered into Collaboration Agreement with Bristol-Myers Squibb Company valued at upfront payment of $15 million (effective 2026-01-21).
“On January 21, 2026, Janux Therapeutics, Inc. (“Janux” or the “Company”) and Bristol-Myers Squibb Company (“BMS”) entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types (the “Collaboration Target”).”
Eric Dobmeier was appointed as Class III Director at Janux Therapeutics, Inc..
“and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.”
Natasha Hernday was appointed as Class II Director at Janux Therapeutics, Inc..
“On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.”
Ron Barrett was appointed as Chair of the Board at Janux Therapeutics, Inc..
“In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.”
Jay Lichter resigned as Director and Chairman at Janux Therapeutics, Inc..
“On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.”
Janux Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss of $14.8 million.
“Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.”
Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023.
“Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.